Pliva's Polfa changes name to avoid confusion
Polfa Krakow SA of Poland has changed its name to Pliva Krakow ZakladyFarmaceutyczne SA for economic and marketing reasons, according to the PAP news agency. The company's president, Edward Surowka, said that the Polfa name has been shared with other companies, so when the firm marketed its products it also promoted those of its competitors.
Croatian drugmaker Pliva has an 81.5% stake in the former Polfa, which will enable the erstwhile Polfa to use Pliva's extensive international trading network. Pliva Krakow is planning to launch a number of drugs, which are currently undergoing registration with the Polish Institute of Medicines, this year.
By purchasing its stake in Polfa Krakow, Pliva undertook to invest $70 million in the Polish drugs producer. Investments in 1998 were worth some $15 million. Pliva Krakow increased its workforce from 1,250 to 1,310 in 1998 and is looking to further raise its employee numbers. The average pay at the company is said to have increased by around 40% last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze